ZNF703 gene amplification at 8p12 specifies luminal B breast cancer

Luminal B breast cancers represent a fraction of oestrogen receptor (ER)‐positive tumours associated with poor recurrence‐free and disease‐specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B...

Full description

Saved in:
Bibliographic Details
Published inEMBO molecular medicine Vol. 3; no. 3; pp. 153 - 166
Main Authors Sircoulomb, Fabrice, Nicolas, Nathalie, Ferrari, Anthony, Finetti, Pascal, Bekhouche, Ismahane, Rousselet, Estelle, Lonigro, Aurélie, Adélaïde, José, Baudelet, Emilie, Esteyriès, Séverine, Wicinski, Julien, Audebert, Stéphane, Charafe‐Jauffret, Emmanuelle, Jacquemier, Jocelyne, Lopez, Marc, Borg, Jean‐Paul, Sotiriou, Christos, Popovici, Cornel, Bertucci, François, Birnbaum, Daniel, Chaffanet, Max, Ginestier, Christophe
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.03.2011
WILEY‐VCH Verlag
EMBO Press
Wiley Open Access
WILEY-VCH Verlag
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Luminal B breast cancers represent a fraction of oestrogen receptor (ER)‐positive tumours associated with poor recurrence‐free and disease‐specific survival in all adjuvant systemic treatment categories including hormone therapy alone. Identification of specific signalling pathways driving luminal B biology is paramount to improve treatment. We have studied 100 luminal breast tumours by combined analysis of genome copy number aberrations and gene expression. We show that amplification of the ZNF703 gene, located in chromosomal region 8p12, preferentially occurs in luminal B tumours. We explored the functional role of ZNF703 in luminal B tumours by overexpressing ZNF703 in the MCF7 luminal cell line. Using mass spectrometry, we identified ZNF703 as a co‐factor of a nuclear complex comprising DCAF7, PHB2 and NCOR2. ZNF703 expression results in the activation of stem cell‐related gene expression leading to an increase in cancer stem cells. Moreover, we show that ZNF703 is implicated in the regulation of ER and E2F1 transcription factor. These findings point out the prominent role of ZNF703 in transcription modulation, stem cell regulation and luminal B oncogenesis. →See accompanying Closeup by Vessela Kristensen DOI https://doi.org/10.1002/emmm201100128
Bibliography:Contributed equally.
PMCID: PMC3395112
Present address: Fondation Synergie Lyon Cancer, Centre Léon Bérard, Lyon, France
Present address: MaRS Centre Toronto Medical Discovery district, Toronto, Ontario, Canada
Present address: Texas Tech University, Lubbock, Texas, USA
Present address: Génétique Médicale, Hôpital de la Timone, Marseille, France
Present address: Faculté de Médecine, CRN2M, UMR6231, IFR Jean Roche, Secteur Nord, Université de la Méditerranée, Marseille, France
Present address: Unité de Pharmacologie Clinique Expérimentale et Thérapeutique, CHU La Timone, Marseille, France
ISSN:1757-4676
1757-4684
DOI:10.1002/emmm.201100121